1. Home
  2. RXST vs AGEN Comparison

RXST vs AGEN Comparison

Compare RXST & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo RxSight Inc.

RXST

RxSight Inc.

HOLD

Current Price

$6.24

Market Cap

232.2M

Sector

Health Care

ML Signal

HOLD

Logo Agenus Inc.

AGEN

Agenus Inc.

HOLD

Current Price

$7.03

Market Cap

274.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RXST
AGEN
Founded
1997
1994
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
232.2M
274.8M
IPO Year
2021
1999

Fundamental Metrics

Financial Performance
Metric
RXST
AGEN
Price
$6.24
$7.03
Analyst Decision
Hold
Buy
Analyst Count
10
2
Target Price
$9.78
$14.50
AVG Volume (30 Days)
921.7K
8.2M
Earning Date
05-06-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
100.00
EPS
N/A
1.02
Revenue
N/A
$42,877,086.00
Revenue This Year
N/A
$107.63
Revenue Next Year
$10.06
N/A
P/E Ratio
N/A
$7.34
Revenue Growth
N/A
89.95
52 Week Low
$4.48
$2.71
52 Week High
$13.22
$8.85

Technical Indicators

Market Signals
Indicator
RXST
AGEN
Relative Strength Index (RSI) 58.58 66.62
Support Level $5.90 $3.09
Resistance Level $6.53 $8.70
Average True Range (ATR) 0.35 0.74
MACD 0.07 0.12
Stochastic Oscillator 74.55 65.22

Price Performance

Historical Comparison
RXST
AGEN

About RXST RxSight Inc.

RxSight Inc is a commercial-stage medical technology company dedicated to improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The company operates and manages its business in one reportable segment, the research and development, manufacture, and sale of light adjustable lenses and related capital equipment.

About AGEN Agenus Inc.

Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.

Share on Social Networks: